The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) received mixed ratings from 8 analysts, with a shift towards more bullish perspectives in the last 30 days. The average 12-month price target is now $67.12, down from $69.40. Analysts' actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to the company's performance and market conditions. Ionis, known for its antisense technology and drugs like Spinraza and Qalsody, shows a strong revenue growth rate of 113.65% but faces challenges in market capitalization, ROE, ROA, and debt management.
May 08, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ionis Pharmaceuticals has seen a mix of analyst ratings with a slight shift towards bullishness. The average price target has decreased slightly, indicating a cautious optimism among analysts. The company's strong revenue growth contrasts with challenges in market capitalization, ROE, ROA, and high debt levels.
The mixed analyst ratings and the slight decrease in the average price target suggest a cautious market sentiment towards Ionis Pharmaceuticals. Despite the strong revenue growth, the company's financial challenges, such as lower market capitalization and high debt levels, may temper short-term stock performance expectations.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100